RT Journal Article SR Electronic T1 Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.08.13.20157222 DO 10.1101/2020.08.13.20157222 A1 Kasopefoluwa Y. Oguntuyo A1 Christian S. Stevens A1 Chuan-Tien Hung A1 Satoshi Ikegame A1 Joshua A. Acklin A1 Shreyas S. Kowdle A1 Jillian C. Carmichael A1 Hsin-Ping Chiu A1 Kristopher D. Azarm A1 Griffin D. Haas A1 Fatima Amanat A1 Jéromine Klingler A1 Ian Baine A1 Suzanne Arinsburg A1 Juan C. Bandres A1 Mohammed N.A. Siddiquey A1 Robert M. Schilke A1 Matthew D. Woolard A1 Hongbo Zhang A1 COVIDAR Argentina Consortium A1 Andrew J. Duty A1 Thomas A. Kraus A1 Thomas M. Moran A1 Domenico Tortorella A1 Jean K. Lim A1 Andrea V. Gamarnik A1 Catarina E. Hioe A1 Susan Zolla-Pazner A1 Stanimir S. Ivanov A1 Jeremy P. Kamil A1 Florian Krammer A1 Benhur Lee YR 2020 UL http://medrxiv.org/content/early/2020/08/27/2020.08.13.20157222.abstract AB The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous BSL3 conditions which limits high throughput screening of patient and vaccine sera. Myriad BSL-2 compatible surrogate virus neutralization assays (VNAs) have been developed to overcome this barrier. Yet, there is marked variability between VNAs and how their results are presented, making inter-group comparisons difficult. To address these limitations, we developed a standardized VNA using VSVAG-based CoV-2-S pseudotyped particles (CoV2pp) that can be robustly produced at scale and generate accurate neutralizing titers within 18 hours post-infection. Our standardized CoV2pp VNA showed a strong positive correlation with CoV2-S ELISA and live virus neutralizations in confirmed convalescent patient sera. Three independent groups subsequently validated our standardized CoV2pp VNA (n>120). Our data show that absolute (abs) IC50, IC80, and IC90 values can be legitimately compared across diverse cohorts, highlight the substantial but consistent variability in neutralization potency across these cohorts, and support the use of absIC80 as a more meaningful metric for assessing the neutralization potency of vaccine or convalescent sera. Lastly, we used our CoV2pp in a screen to identify ultra-permissive 293T clones that stably express ACE2 or ACE2+TMPRSS2. When used in combination with our CoV2pp, we can now produce CoV2pp sufficient for 150,000 standardized VNA/week.Importance Vaccines and antibody-based therapeutics like convalescent plasma therapy are premised upon inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) is an essential part of determining vaccine or therapeutic efficacy. However, such efficacy testing is limited by the inherent dangers of working with the live virus, which requires specialized high-level biocontainment facilities. We therefore developed a standardized replication-defective pseudotyped particle system that mimics entry of live SARS-CoV-2. This tool allows for the safe and efficient measurement of NATs, determination of other forms of entry inhibition, and thorough investigation of virus entry mechanisms. Four independent labs across the globe validated our standardized VNA using diverse cohorts. We argue that a standardized and scalable assay is necessary for meaningful comparisons of the myriad of vaccines and antibody-based therapeutics becoming available. Our data provide generalizable metrics for assessing their efficacy.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed for a U.S. Provisional Patent (Application Number 63/063,041) for the work presented here.Funding StatementThe authors acknowledge the following funding: KYO and CS were supported by Viral-Host Pathogenesis Training Grant T32 AI07647; KYO was additionally supported by F31 AI154739. SI and CTH were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively. BL acknowledges flexible funding support from NIH grants R01 AI123449, R21 AI1498033, and the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the ISMMS. JPK and SSI acknowledge funding from a LSUHS COVID-19 intramural grant. JPK and SSI acknowledge additional funding from NIH grants AI116851 and AI143839, respectively. This work was further supported by the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub, NIH grant U54TR001433 to the Department of Medicine of the ISMMS to SZP. We also acknowledge funding from the Department of Veterans Affairs Merit Review Grant I01BX003860 (CEH, SZP, and JK), Research Career Scientist Award 1IK6BX004607 (CEH), and NIH grant AI139290 (CEH, SZP). We thank Randy A. Albrecht for oversight of the conventional BSL3 biocontainment facility. Work in the Krammer laboratory was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (FK), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (FK) and the generous support of the JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic donations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patient sera were acquired after approval by the respective institutional review boards and/or equivalent oversight bodies (Bioethics Committee, Independent Ethics Committee) are indicated: (1) Mount Sinai Hospital Institutional Review Board (New York, USA), (2) Louisiana State University Health Sciences Center, Shreveport (LSUHS, Louisiana, USA), and (3) Fundacion Instituto Leloir-CONICET, Universidad Nacional de San Martin, Laboratorio Lemos SRL, Universidad de Buenos Aires (COVIDAR Argentina Consortium, Buenos Aires, Argentina). Samples were de-identified at the source institutions or by the respective PIs of the IRB approved protocols for sample collection before analysis performed in this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.